CA2535550A1 - Treatment for acne vulgaris and method of use - Google Patents

Treatment for acne vulgaris and method of use Download PDF

Info

Publication number
CA2535550A1
CA2535550A1 CA 2535550 CA2535550A CA2535550A1 CA 2535550 A1 CA2535550 A1 CA 2535550A1 CA 2535550 CA2535550 CA 2535550 CA 2535550 A CA2535550 A CA 2535550A CA 2535550 A1 CA2535550 A1 CA 2535550A1
Authority
CA
Canada
Prior art keywords
treatment
acne vulgaris
ethoxylate
composition
exchanged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2535550
Other languages
French (fr)
Inventor
William M. Yarbrough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yarbrough William M Foundation
Original Assignee
William M. Yarbrough
The William M. Yarbrough Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William M. Yarbrough, The William M. Yarbrough Foundation filed Critical William M. Yarbrough
Priority to PCT/US2003/025207 priority Critical patent/WO2005018629A1/en
Publication of CA2535550A1 publication Critical patent/CA2535550A1/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39Derivatives containing from 2 to 10 oxyalkylene groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/72Cosmetics or similar toilet preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84Cosmetics or similar toilet preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86Polyethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Abstract

A treatment for Acne Vulgaris is provided for in a topical treatment.
According to the invention, a method is provided for applying composition substances to the infected area, working the composition into the infected area, and removing the composition from the infected area. The composition comprises at least one ethoxylate in combination with Sodium Lauroyl Sarcosinate. Alternatively, the ethoxylate can be exchanged for a methoxylate or a propoxylate. An inert scrubbing agent, such as polyethylene beads, can also be included. Acetylated lanolin alcohol, sodium Lauroyl Sarcosinate, EDTA, a foam stabilizer, and water can also be added to the composition to assist performance.

Description

1 Invention: Treatment for Acne Vulgaris and Method of Use 2 Inventor: William M. Yarbrough 3 I. FIELD OF THE INVENTION

4 The present invention relates to a composition including surfactants for the treatment of acne vulgaris. Methods of use are also included 6 TI. BACKGROUND OF THE INVENTION AND PRIOR ART
7 Acne vulgaris (or "acne") is a disorder of the sebaceous glands. It is 8 characterized by lesions that are either non-inflammatory or inflammatory papules and 9 nodules. Non-inflammatory papules may be open, commonly referred to as "blackheads", or closed, commonly referred to as "whiteheads". As a group, non-11 inflammatory. papules are called comedones. Closed comedones can lead to 12 inflammatory nodules, papules, and pustules. Severe cases of acne vulgaris can lead to 13 scars characterized by pitting.
14 It is believed that acne results from partial rupture of a partially inflamed follicle. The follicle then spills its components, thereby resulting in the development of a 16 perifollicular inflammatory process. Generally, fresh lesions are sterile, but later gram-17 positive diptheroids are present. Many times the skin will have a greasy look to it; this is 18 probably due, at least in part, to the release of fatty acids during lipolysis induced by P.
19 acnes.
Acne can be a serious problem. It generally manifests itself during adolescence 21 and spontaneously resolves in the late teens or early twenties; although for some, it can be 22 a life long problem. Mild to moderate acne is most often treated with topical agents.

INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use INVENTOR: . William Yarbrough 1 More severe cases are treated with incision and drainage of lesions, ultraviolet light 2 therapy, and systemic antibiotics.
3 The prior art is replete with compositions for use in the treatment of acne.
4 Topical agents, such as benzoyl peroxide, are thought to decrease bacteria and are often used in the treatment of acne. These treatments are found in many forms, lotions, gels, 6 pads, etc. and are generally available over the counter. Retinol in various forms has been 7 more recently proposed by various Inventors. There are also many soaps used in the 8 treatment of acne. A major shortcoming of most of the prior art is that they often do not 9 penetrate sufficiently and they leave the skin dry.
II. OBJECTS OF THE INVENTION
11 It is an obj ect of the present invention to provide a treatment that helps to alleviate 12 the local signs and symptoms caused by acne vulgaris.
13 It is a further object of the present invention to provide a method of use of the 14 present inventive treatment.
It is yet another object of the present invention to provide a treatment that 16 includes at least a first nonyl phenyl ethoxylate and sodium lauroyl sarcosinate to which a 17 second nonyl phenyl ethoxylate, acetylated lanolin alcohol, EDTA, a foam stabilizer, 18 water, and inert polyethylene granules can be added without altering the effectiveness of 19 the treatment.
It is a yet further object of the present invention to provide a treatment that is safe 21 to use.

INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use INVENTOR: William Yarbrough 1 It is yet another object of the present invention to provide such treatment that is 2 topical, can be purchased over the counter, and is economical.
3 IV. SUMMARY OF THE INVENTION
4 The above objects of the invention are provided for in a topical treatment for acne vulgaris. According to the invention, a method is provided for applying a composition of 6 substances to the infected area, working the composition into the infected area, and 7 removing the composition from the infected area. The composition comprises at least 8 one ethoxylate in combination with Sodium Lauroyl Sarcosinate (or "SLS"). An inert 9 scrubbing agent, such as polyethylene beads, can also be included to the formula.
Acetylated lanolin alcohol, a second ethoxylate, EDTA, a foam stabilizer, and water can 11 also be added to the composition without effecting performance.
12 Other formulas that keep the polarity similar to that of the inventive formula will 13 also work. To keep the polarity similar, it is necessary for the compound to have similar 14 characteristics, such as Carbon chains, carbonyl groups, Nitrogen bound to Carbon, Aromatic ring(s), Oxylate groups, and appropriate functional groups at the ends of the 16 individual molecules. The ideal substitute chemicals would have all of the characteristics 17 mentioned above, but it is not necessary to have every one of those as listed. For 18 example, if the functional groups at the ends of the individual molecules are exchanged 19 for other functional groups that retain the ability to undergo an emulsion polymerization, then the effectiveness of the compound is also retained. Another example is to change the 21 ethoxylate to a methoxylate or propoxylate. These formations would still retain a similar INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use INVENTOR: William Yarbrough 1 polarity but would be different compounds with different characteristics.
Yet another 2 example would be to exchange triply bound Nitrogen with a doubly bound or perhaps 3 Nitrogen with 4 Carbons bound to it.
4 V. DETAILED DESCRIPTION OF THE INVENTION
Chemical analysis and research has revealed that two of the component parts of 6 the inventive composition are principally involved in its effectiveness as an acne 7 treatment: an ethoxylate and Sodium Lauroyl Sarcosinate ("SLS"). The ethoxylate is 8 preferably a nonyl phenol ethoxylate.
9 The Inventor has also found, however, that other formulas that keep the polarity similar to that of the inventive formula will also work. To keep the polarity similar, it is 11 necessary for the compound to have similar characteristics, such as Carbon chains, 12 carbonyl groups, Nitrogen bound to Carbon, Aromatic ring(s), Oxylate groups, and 13 appropriate functional groups at the ends of the individual molecules. The ideal 14 substitute chemicals would have all of the characteristics mentioned above, but it is not necessary to have every one of those as listed. For example, if the functional groups at the 16 ends of the individual molecules are exchanged for other functional groups that retain the 17 ability to undergo an emulsion polymerization, then the effectiveness of the compound is 18 also retained. Another example is to change the ethoxylate to a methoxylate or 19 propoxylate. These formations would still retain a similar polarity but would be different compounds with different characteristics. Yet another example would be to exchange INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use INVENTOR: William Yarbrough 1 triply bound Nitrogen with a doubly bound or perhaps Nitrogen with 4 Carbons bound to 2 it.
3 The inventor has also discovered that the addition of an inert scrubbing agent 4 improves the action of the inventive composition. The beads should be large enough to be effective but not so large as to cause abrasions. The inventor suggests beads in the 6 range of 5 to SO microns with an average size being approximately 25 microns or 50 7 mesh.
8 To make the inventive composition, an exact ratio of ethoxylate to SLS is not 9 critical. The only requirement is that the ethoxylate is completely reacted with the SLS, creating a polymer. This will vary with the ethoxylate used, but the Inventor has 11 determined that a ratio of ethoxylate-to- SLS of 1. S :2 is preferred. The amount by weight 12 of polyethylene beads can vary according to the grittiness desired. The Inventor has 13 found that a formula of ethoxylate:SLS:polyethylene of 40:20:40 is preferred but that 14 formulas of other concentrations are useful. Thus, for production purposes, formulas having SLS ranging from 10 to 20 % by weight, ethoxylate ranging from 20 to 40 % by 16 weight, and polyethylene beads from 20 to 50% by weight are reasonable. But again, the 17 formula is not restricted to these ranges, which ranges are presented for example purposes 18 only.
19 Also, a cutting agent that does not chemically react with the composition may be added. The cutting agent makes the overall composition flow more easily, thereby INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use INVENTOR: William Yarbrough 1 enabling more packaging options, such as tubes. The cutting agent must be added only in 2 sufficient amount that it promotes flow but does not effect the action of the composition.
3 In use, an sufficient amount of the composition is used to cover the infected area, 4 the composition is applied to an infected area and worked over the area by a scrubbing motion. After sufficient time has elapsed to ensure that the infected area has been 6 adequately exposed to the composition such that they area feels clean, approximately ten 7 to thirty seconds for the typical person, the area is rinsed cleaned.

Claims (32)

1. A Treatment for Acne Vulgaris comprising sodium lauroyl sarcosinate and a nonyl phenyl ethoxylate in combination.
2. The treatment for Acne Vulgaris of Claim 1 further including a second nonyl phenyl ethoxylate.
3. The treatment for Acne Vulgaris of Claim 1 further including acetylated lanolin alcohol.
4. The treatment for Acne Vulgaris of Claim 1 further including polyethylene granules.
5. The treatment for Acne Vulgaris of Claim 1 further including water.
6. The treatment for Acne Vulgaris of Claim 1 further including ethylenediaminetetraacetic acid.
7. The treatment for Acne Vulgaris of Claim 1 further including a foam stabilizing agent.
8. The treatment for Acne Vulgaris of Claim 1 further including a cutting agent.
9. The cutting agent of Claim 8 being selected from the group of aqueous based solutions and oil based solutions.
10. The treatment for Acne Vulgaris of Claim 1 wherein the ethoxylate is exchanged for a methoxylate.
11. The treatment for Acne Vulgaris of Claim 1 wherein the ethoxylate is exchanged for a propoxylate.
12. A treatment for Acne Vulgaris comprising an ethoxylate, sodium lauroyl sarcosinate, and scrubbing means.
13. The treatment for Acne Vulgaris of Claim 12 wherein the scrubbing mean is polyethylene beads.
14. The treatment for Acne Vulgaris of Claim 12 further including a cutting agent.
15. The treatment for Acne Vulgaris of Claim 12 wherein the ethoxylate is exchanged for a methoxylate.
16. The treatment for Acne Vulgaris of Claim 12 wherein the ethoxylate is exchanged for a propoxylate.
17. A treatment for Acne Vulgaris comprising: a first ethoxylate, a second ethoxylate, acetylated lanolin alcohol, sodium lauroyl sarcosinate, EDTA, a foam stabilizer, water, and inert polyethylene granules.
18. The treatment for Acne Vulgaris of Claim 17 wherein the first ethoxylate is exchanged for a methoxylate.
19. The treatment for Acne Vulgaris of Claim 17 wherein the first ethoxylate is exchanged for a propoxylate.
20. A treatment for Acne Vulgaris comprising an ethoxylate, sodium lauroyl sarcosinate, and EDTA.
21. The treatment for Acne Vulgaris of Claim 20 wherein the ethoxylate is exchanged for a methoxylate.
22. The treatment for Acne Vulgaris of Claim 20 wherein the ethoxylate is exchanged for a propoxylate.
23. A method for treating Acne Vulgaris comprising the steps of:
preparing a composition comprising an ethoxylate and sodium lauroyl sarcosinate;
applying the composition to an infected area;
permitting the composition to remain on the infected area a sufficient amount of time to enable the composition of matter to cause an effect; and, removing the composition from the infected area.
24. The method of Claim 23 wherein preparing the composition further includes adding second ethoxylate.
25. The method of Claim 23 wherein preparing the composition further includes adding acetylated lanolin alcohol.
26. The method of Claim 23 wherein preparing the composition further includes adding acetylated polyethylene granules.
27. The method of Claim 23 wherein preparing the composition further includes adding water.
28. The method of Claim 23 wherein preparing the composition further includes EDTA.
29. The method of Claim 23 wherein preparing the composition further includes a foam stabilizer.
30. The method of Claim 23 further including the step of adding a thinning agent to the composition.
31. The method of Claim 23 wherein the ethoxylate is exchanged for a methoxylate.
32. The method of Claim 23 wherein the ethoxylate is exchanged for a propoxylate.
CA 2535550 2003-08-12 2003-08-12 Treatment for acne vulgaris and method of use Abandoned CA2535550A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2003/025207 WO2005018629A1 (en) 2003-08-12 2003-08-12 Treatment for acne vulgaris and method of use

Publications (1)

Publication Number Publication Date
CA2535550A1 true CA2535550A1 (en) 2005-03-03

Family

ID=34215304

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2535550 Abandoned CA2535550A1 (en) 2003-08-12 2003-08-12 Treatment for acne vulgaris and method of use

Country Status (5)

Country Link
EP (1) EP1656128A4 (en)
JP (1) JP2007521234A (en)
AU (1) AU2003264053A1 (en)
CA (1) CA2535550A1 (en)
WO (1) WO2005018629A1 (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008074840A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2008074839A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
FR2923383B1 (en) * 2007-11-08 2010-03-19 Oreal Use of an n-acylated sarcosinate as a microbial anti-adhesion agent.
WO2009068627A2 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
US20110091462A1 (en) 2008-03-05 2011-04-21 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
WO2009124931A2 (en) 2008-04-07 2009-10-15 Ablynx Nv Amino acid sequences directed against the notch pathways and uses thereof
KR20110020825A (en) 2008-05-16 2011-03-03 아블린쓰 엔.브이. Amino acid sequences directed against cxcr4 and other gpcrs and compounds comprising the same
SI2285408T1 (en) 2008-06-05 2019-02-28 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
WO2010043650A2 (en) 2008-10-14 2010-04-22 Ablynx Nv Amino acid sequences directed against cellular receptors for viruses and bacteria
JP5823871B2 (en) 2008-12-10 2015-11-25 アブリンクス エン.ヴェー. Amino acid sequences directed against the Angiopoietin / Tie system for the treatment of diseases and disorders associated with angiogenesis and polypeptides comprising the same
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
EP3461844A3 (en) 2009-04-10 2019-05-15 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
ES2551854T3 (en) 2009-04-30 2015-11-24 Ablynx N.V. Procedure for the production of domain antibodies
EP3205670A1 (en) 2009-06-05 2017-08-16 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
US9150640B2 (en) 2009-07-10 2015-10-06 Ablynx N.V. Method for the production of variable domains
EP2473528B1 (en) 2009-09-03 2014-12-03 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP2513145B1 (en) 2009-12-14 2018-01-24 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
US9713589B2 (en) 2010-02-11 2017-07-25 Ablynx N.V. Methods and compositions for the preparation of aerosols
EP2552962B1 (en) 2010-03-26 2016-03-23 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
SG185354A1 (en) 2010-05-20 2012-12-28 Ablynx Nv Biological materials related to her3
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
US20130261288A1 (en) 2010-10-29 2013-10-03 Ablynx N.V. Method for the production of immunoglobulin single variable domains
CN108341868A (en) 2010-11-05 2018-07-31 酵活有限公司 There is the antibody design of the stabilization heterodimeric of mutation in Fc structural domains
EA201390666A1 (en) 2010-11-08 2013-11-29 Новартис Аг Cxcr2-bonding polypeptides
EP2691418A1 (en) 2011-03-28 2014-02-05 Ablynx N.V. Bispecific anti-cxcr7 immunoglobulin single variable domains
ES2688591T3 (en) 2011-03-28 2018-11-05 Ablynx N.V. Method for producing solid formulations comprising individual variable domains of immunoglobulin
AU2012257942B8 (en) 2011-05-05 2015-09-17 Merck Patent Gmbh Amino acid sequences directed against IL-17A, IL-17F and/or IL17-A/F and polypeptides comprising the same
EP2707382B1 (en) 2011-05-09 2019-07-17 Ablynx NV Method for the production of immunoglobulin single variable domains
CN103732625A (en) 2011-05-27 2014-04-16 埃博灵克斯股份有限公司 Inhibition of bone resorption with RANKL binding peptides
EP2723772A1 (en) 2011-06-23 2014-04-30 Ablynx N.V. Immunoglobulin single variable domains directed against ige
DK2747782T3 (en) 2011-09-23 2018-04-23 Ablynx Nv Long-term inhibition of interleukin-6-mediated signal transmission
BR112014010580A2 (en) 2011-11-04 2017-05-02 Zymeworks Inc stable heterodimeric antibody design with fc domain mutations
WO2013166594A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
EP3233910A1 (en) 2014-12-19 2017-10-25 Ablynx N.V. Cysteine linked nanobody dimers
SE1650679A1 (en) 2016-05-19 2017-11-20 Biocool Ab New use of product for skin treatment
EP3468530A1 (en) 2016-06-10 2019-04-17 Clarity Cosmetics Inc. Non-comedogenic hair and scalp care formulations and method for use
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
WO2018050833A1 (en) 2016-09-15 2018-03-22 Ablynx Nv Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
CN110177809A (en) 2016-11-16 2019-08-27 埃博灵克斯股份有限公司 Polypeptide can be raised in conjunction with the T cell of CD123 and TCR α/β
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
WO2018158335A1 (en) 2017-02-28 2018-09-07 Vib Vzw Means and methods for oral protein delivery
WO2018206734A1 (en) 2017-05-11 2018-11-15 Vib Vzw Glycosylation of variable immunoglobulin domains
WO2018220225A1 (en) 2017-06-02 2018-12-06 Ablynx Nv Aggrecan binding immunoglobulins
WO2018220236A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Polypeptides binding adamts5, mmp13 and aggrecan
TW201920287A (en) 2017-06-02 2019-06-01 德商麥克專利有限公司 ADAMTS binding immunoglobulins
TW201906870A (en) 2017-06-02 2019-02-16 德商麥克專利有限公司 Immunoglobulin binding of mmp13
WO2019016237A1 (en) 2017-07-19 2019-01-24 Vib Vzw Serum albumin binding agents
WO2019086548A1 (en) 2017-10-31 2019-05-09 Vib Vzw Novel antigen-binding chimeric proteins and methods and uses thereof
WO2019154867A1 (en) 2018-02-06 2019-08-15 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
WO2019166622A1 (en) 2018-03-01 2019-09-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
WO2019180204A1 (en) 2018-03-23 2019-09-26 Université Libre de Bruxelles Wnt signaling agonist molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1539031A (en) * 1975-02-22 1979-01-24 Beecham Group Ltd Pharmaceutical compositions
US4147782A (en) * 1976-06-24 1979-04-03 William H. Rorer, Inc. Pharmaceutical detergent composition
AU5318399A (en) * 1998-07-20 2000-02-07 Victor Chamberlain Acne treatment compositions
US7008963B2 (en) * 1999-07-03 2006-03-07 The William M. Yarbrough Foundation Urushiol induced contact dermatitis solution
US6423746B1 (en) * 1999-07-03 2002-07-23 The William M. Yarbrough Foundation Urushiol induced contact dermatitis and method of use

Also Published As

Publication number Publication date
JP2007521234A (en) 2007-08-02
AU2003264053A1 (en) 2005-03-10
WO2005018629A1 (en) 2005-03-03
EP1656128A1 (en) 2006-05-17
EP1656128A4 (en) 2007-02-28

Similar Documents

Publication Publication Date Title
CN1215763C (en) Alcohol-containing anti-microbial compositions with cosmetic apparatus
EP0004755B1 (en) Liquid detergent cleansing compositions having low ocular and skin irritation
US5728391A (en) Hyaluronic acid and its salt for treating skin diseases
DE69532888T2 (en) Liquid milder antimicrobial detergent
CA2278521C (en) Two phase skin preparations comprising lipophilic and hydrophilic components
JP5068408B2 (en) Deep penetration antimicrobial composition
US6183757B1 (en) Mild, rinse-off antimicrobial cleansing compositions which provide improved immediate germ reduction during washing
US20030064969A1 (en) Novel compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use
AU720008B2 (en) Medical composition and use thereof for the manufacture of topical barrier formulation, a UV-radiation absorbing formulation, or an antiviral, antifungal, or antiinflammatory formulation
US20040058878A1 (en) Antimicrobial and sporicidal composition
US5512200A (en) Low pH Acidic Compositions
US3798182A (en) Mildness additive
US8101163B2 (en) Transdermal compositions
Mukhopadhyay Cleansers and their role in various dermatological disorders
CA2044795C (en) Dermatological composition based on an aqueous phase
Kandaswamy et al. Root canal irrigants
EP0654270B1 (en) Preparation for the treatment of acne, seborrheic dermatitis and other skin diseases
JP3819765B2 (en) Hair cosmetic composition having antidandruff formation effect
US5480633A (en) Mild cleanser and conditioner to yield soft smooth skin
DE69839177T2 (en) Antimicrobial cleanser with high glycerin content
JP2004523550A (en) Body cleansing composition containing particles dispersion in oil
CN1079663C (en) Mild shower gel composition comprising fatty alcohol which imparts improved lathering and thickneing properties
US5866142A (en) Skin treatment system
EP0741557B1 (en) A method and composition for promoting improved adhesion to substrates
RU2272612C2 (en) Compositions showing enhanced precipitation of active compound for regional effect on surface

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead